Finally, the first and the largest #metaanalysis on the upfront combination lipid lowering therapy (#LLT) of moderate to high intensity #statin therapy and #ezetimibe vs statin monotherapy has been released in the Mayo Clinic Proceedings by Elsevier.
Based on the data from 14 studies with 108,373 very high-risk #patients we showed that #combination LLT:
👉 significantly more effectively reduced #LDLC level from baseline (by mean −12.96 mg/dL);
👉 significantly reduced all-cause #mortality (by 19%; with the longer the better results), major adverse cardiovascular events (#MACE; by 18%) and #stroke incidence (by 17%) when compared with statin monotherapy;
👉 the network meta-analysis (#NMA) confirmed these results with more pronounced values: significant additional LDL-C reduction by −15.16 mg/dL, 49% reduction of all-cause mortality and 39% reduction of MACE in comparison to high intensity statin therapy;
👉 NMA also revealed that moderate-intensity statins combined with ezetimibe had a significantly lower #discontinuation rate compared with high-intensity statins (by 44%).
Forthcoming #guidelines should consider the #upfront lipid-lowering combination therapy for more effective LDL-C goal achievement and significant reduction of #cardiovascular disease outcomes and mortality in high- and very high-risk patients.
For the full paper please see: https://www.sciencedirect.com/science/article/abs/pii/S0025619625000758?dgcid=author#fig1
These results have been also press-released and have been already published in the:
▶️ BBC Science Focus: LINK
▶️ Medical Xpress: LINK
▶️ EurekAlert!: LINK
International Lipid Expert Panel (ILEP) Vikash J. Song Peng A. Aanchal Sawhney Novonil Deb Pierre AMARENCO Željko Reiner Ivan Pećin Chip Lavie Peter Penson Peter P. Toth, MD, PhD The Johns Hopkins University School of Medicine Liverpool John Moores University Medical University of Lodz Katolicki Uniwersytet Lubelski Jana Pawła II
